SEP-363856在TAAR1与5HT1A受体中的结合特征及其对新药设计的启示
本文简述TAAR1与5HT1A受体在精神分裂症中的作用,并利用分子动力学模拟分析SEP-363856与两受体的结合特征。模拟显示SEP-363856结合于两受体配体结合域内一组保守残基,主要与带负电的天冬氨酸残基(TAAR1的Asp1033.32、5HT1A的Asp1163.32)相互作用。SEP-363856在TAAR1中的结合涉及比5HT1A更多的芳香族接触,为理解其药理独特性及设计靶向这些受体的新药提供依据。
要点
- SEP-363856靶向非多巴胺受体TAAR1和5HT1A,临床试验阳性提示其治疗精神分裂症潜力。
- 分子动力学模拟显示SEP-363856与TAAR1和5HT1A配体结合域内一组保守残基相互作用。
- 主要结合涉及TAAR1的Asp1033.32和5HT1A的Asp1163.32,且TAAR1结合有更多芳香族接触。
核心结论
- SEP-363856与TAAR1和5HT1A受体配体结合域内一组保守残基结合,主要依赖与带负电天冬氨酸残基的相互作用。
- SEP-363856在TAAR1中的结合涉及比5HT1A更多的芳香族接触,这有助于理解其药理独特性并指导新药设计。
研究设计与样本
- 本文为视角文章,简要概述TAAR1和5HT1A受体在精神分裂症中的作用,并采用分子动力学模拟探究SEP-363856与两受体的结合特征。
主要发现
- 分子动力学模拟表明SEP-363856与TAAR1和5HT1A配体结合域内一小群共同保守残基相互作用。
- SEP-363856的主要相互作用涉及结合至带负电的天冬氨酸残基:TAAR1的Asp1033.32和5HT1A的Asp1163.32。
- 总体而言,SEP-363856在TAAR1中的结合相比5HT1A涉及更多芳香族接触。
关键数值与推荐
- SEP-363856主要结合残基为TAAR1的Asp1033.32和5HT1A的Asp1163.32。
- SEP-363856在TAAR1中的结合比在5HT1A中涉及更多芳香族接触。
临床怎么用
- 分子动力学模拟结果有助于理解SEP-363856靶向TAAR1和5HT1A受体的药理独特性,为设计治疗精神分裂症及相关疾病的新型候选药物提供结构基础。
局限性
- 本文为视角文章,主要基于分子动力学模拟,未提供临床疗效或安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current medications for schizophrenia typically modulate dopaminergic neurotransmission. While affecting positive symptoms, antipsychotic drugs have little clinical effect on negative symptoms and cognitive impairment. Moreover, newer 'atypical' antipsychotic drugs also have significant metabolic adverse-effects. The recent positive clinical trial of the novel drug candidate SEP-363856, which targets non-dopamine receptors (trace amine-associated receptor and the 5HT1A receptor), is a potentially promising development for the management of schizophrenia. In this perspective, we briefly overview the role of TAAR1 and the 5HT1A receptor in schizophrenia and explore the specific binding characteristics of SEP-363856 at these receptors. Molecular dynamics simulations (MDS) indicate that SEP-363856 interacts with a small, common set of conserved residues within the TAAR1 and 5HT1A ligand-binding domain. The primary interaction of SEP-363856 involves binding to the negatively charged aspartate residue (Asp1033.32, TAAR1; Asp1163.32, 5HT1A). In general, the binding of SEP-363856 within TAAR1 involves a greater number of aromatic contacts compared to 5HT1A. MDS provides important insights into the molecular basis of binding site interactions of SEP-363856 with TAAR1 and the 5HT1A receptor, which will be beneficial for understanding the pharmacological uniqueness of SEP-363856 and for the design of novel drug candidates for these newly targeted receptors in the treatment of schizophrenia and related disorders.
引用
- Nair PC, Miners JO, McKinnon RA, et al. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Mol Psychiatry. 2021. PMID: 34376825. doi:10.1038/s41380-021-01250-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。